Replies to post #239 on Axsome Therapeutics Inc (AXSM)

[Alan Brown]

Probably 30b

[Paullee]

Wainwright just increased target to 30

[blu_1]

$100M

[smallbio]

I think it will all depends on clinical development.

1) AXS-05
a) STRIDE-1 for TRD 2H 2019,
b) MDD phase 3 still yet to start but 2H 2019 readout,
c) Safety data which is an important aspect.

2) AXS-12 Phase 2 readout 1H 2019.

3) AXS-07 for migraine Phase 3 readout 2H 2019.

IF AXS-05 has no safety issue, and TRD readout is positive, this one alone could take the market cap a few times higher than it is today.

BUT this is biotech & it is impossible to predict trial results.

[smallbio]

I also would like to add that timeline for AXS-05 to play out is quite quick which is a plus.

So it does not take too long to know if AXSM is for real or not.